Vedolizumab [VDZ] is a monoclonal antibody directed against the α4β7 integrin heterodimer, approved for patients with inflammatory bowel diseases [IBD]. This study aimed at identifying immunological variables associated with response to vedolizumab in patients with ulcerative colitis [UC] and Crohn's disease [CD].
Immunological Variables Associated With Clinical and Endoscopic Response to Vedolizumab in Patients With Inflammatory Bowel Diseases
Fantini, Massimo Claudio;Vecchi, Maurizio;
2020-01-01
Abstract
Vedolizumab [VDZ] is a monoclonal antibody directed against the α4β7 integrin heterodimer, approved for patients with inflammatory bowel diseases [IBD]. This study aimed at identifying immunological variables associated with response to vedolizumab in patients with ulcerative colitis [UC] and Crohn's disease [CD].
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Coletta M et al J Crohns Colitis 2020.pdf
Solo gestori archivio
Tipologia:
versione editoriale (VoR)
Dimensione
3.56 MB
Formato
Adobe PDF
|
3.56 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
